Merit Medical Systems, Inc. (MMSI) reported first-quarter 2025 adjusted earnings per share (EPS) of 86 cents, up 14.7% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 14.7%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)GAAP EPS for the quarter was 49 cents, down by a penny year over year.MMSI’s Revenue DetailsRevenues grossed $355.4 million in the reported quarter, up 9.8% year over year on a reported basis. The metric topped the Zacks Consens ...

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - Chief Financial Officer and Treasurer Brian Lloyd - Chief Legal Officer & Corporate Secretary Conference Call Participants Jason Bednar - Piper Sandler Steve Lichtman - Oppenheimer Robbie Marcus - J.P. Morgan Craig Bijou - Bank of America Securities David Rescott - Baird Michael Petusky - Barrington Research Jim ...

For the quarter ended March 2025, Merit Medical (MMSI) reported revenue of $355.35 million, up 9.8% over the same period last year. EPS came in at $0.86, compared to $0.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $352.33 million, representing a surprise of +0.86%. The company delivered an EPS surprise of +14.67%, with the consensus EPS estimate being $0.75.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.67%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.83 per share when it actually produced earnings of $0.93, delivering a surprise of 12.05%.Over the last f ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . (Exact name of registrant as specified in its charter) Utah 87-0447695 (State or other jurisdiction of incorporation or organization) (IRS Employe ...

Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 +1-443-213-0509 Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare sarah.comstock@merit.com mike.piccinino@icrhealthcare.com FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE First Quarter Highlights† Exhibit 99.1 † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are ...

Core Insights - Merit Medical Systems, Inc. reported a revenue of $355.4 million for Q1 2025, reflecting a 9.8% increase compared to Q1 2024 [4][6] - The company achieved a constant currency revenue growth of 10.9% and an organic constant currency revenue increase of 6.0% year-over-year [4][6] - Non-GAAP earnings per share (EPS) rose by 14.8% to $0.86, while GAAP EPS increased by 2.0% to $0.49 [6][9] Financial Performance - The GAAP operating margin improved to 11.5% from 11.1% in the prior year, while the non-GAAP operating margin increased to 19.3% from 17.0% [6][8] - Free cash flow generation was reported at $19.5 million, down 20.5% compared to the previous year [6] - The company’s GAAP net income for Q1 2025 was $30.1 million, compared to $28.2 million in Q1 2024 [9] Revenue Breakdown - Revenue by segment showed significant growth in the Cardiovascular segment, with a 10.6% increase in Cardiac Intervention and a 20.5% increase in OEM [5] - The Endoscopy segment also saw substantial growth, with revenue increasing by 64.2% [7] - Total revenue for the Cardiovascular segment was $338.7 million, up 8.1% year-over-year [5] Guidance and Outlook - The company reaffirmed its total revenue guidance for 2025, projecting revenues between $1.470 billion and $1.490 billion, representing an 8% to 10% year-over-year increase [11] - Non-GAAP EPS guidance was updated to reflect stronger-than-expected Q1 results, now projected between $3.29 and $3.42 [11] - The company anticipates continued stable constant currency growth despite potential impacts from trade policies [5][11] Balance Sheet Highlights - As of March 31, 2025, Merit had cash and cash equivalents of $395.5 million, an increase from $376.7 million at the end of 2024 [10] - Total debt obligations remained stable at $747.5 million [10] - The company had an available borrowing capacity of approximately $697 million [10]

Wall Street analysts expect Merit Medical (MMSI) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $352.33 million, up 8.9% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead o ...

Merit Medical Systems, Inc. (MMSI) recently announced the launch of its new Ventrax Delivery System, designed to enhance precision and control in pulmonary interventions. This latest innovation reflects the company’s ongoing commitment to improving procedural efficiency and outcomes in interventional medicine.With the Ventrax Delivery System, Merit Medical expands its growing electrophysiology and cardiac rhythm management (CRM) portfolio. The system integrates seamlessly with existing tools, aiming to addr ...

Merit Medical (MMSI) shares soared 8.3% in the last trading session to close at $95.79. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.1% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This maker of disposable medical devices is expected to post quarterly earnings of $0.75 per share in its upcomin ...